

WHO Global Malaria Programme

Good practices for selecting and procuring rapid diagnostic tests for malaria





Good practices for selecting and procuring rapid diagnostic tests for malaria



WHO Library Cataloguing-in-Publication Data:

Good practices for selecting and procuring rapid diagnostic tests for malaria.

1. Diagnostic techniques and procedures. 2. Malaria – diagnosis. 3. Diagnostic tests, Routine – methods. 4. Manuals. I. World Health Organization.

ISBN 978 92 4 150112 5 (NLM classification: WC 750)

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20, avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Photos on cover: ©WHO/Silvia Schwarte - Red blood cells: ©Ingram Publishing

Printed in Malta

First published in May 2011, reprinted in November 2012 with changes.

Please consult the WHO Global Malaria Programme web site for the most up-to-date version of all documents (www.who.int/malaria).

Contents

Acknow	vledge	ements	vi		
Abbrev	iatior	18	vii		
Glossar	y		viii		
Introdu	ction	L	1		
	Purpose of the manual and target audience				
	Organization of the manual				
	Malaria				
	Rapid diagnostic tests for malaria				
	Determinants of test performance				
	Pro	curement checklist	6		
Step 1.	Rec	uirements for selecting rapid diagnostic tests	8		
	1.1	Target parasite species and antigens	8		
	1.2	Performance of rapid diagnostic tests	10		
	1.3	WHO recommendations and national treatment guidelines	12		
	1.4	Experience in use of rapid diagnostic tests and availability	14		
	1.5	Additional considerations	14		
	1.6	Summary	15		
Step 2.	Estimating needs		17		
-	2.1	Quantification	17		
	2.2	Transforming estimated needs into orders	21		
Step 3.	Buc	22			
	3.1	National funding	23		
	3.2	Funding from external agencies	23		
Step 4.	Defining technical specifications		24		
	4.1	Target malaria parasite species	24		
	4.2	Target antigens	24		
	4.3	Format and ancillary items	25		
	4.4	Diagnostic performance	28		
	4.5	Sensitivity and specificity	32		
	4.6	Stability of results	32		
	4.7	Declared reading time	32		
	4.8	Shelf-life	32		
	4.9	Packaging and kit contents	32		
	4.10	Labelling	33		
	4.11	Product information for users (package insert)	33		

Step 5.	Procurement method and tender documents				
	5.1 Proc	urement method	35		
	5.2 Tend	er documentation	36		
Step 6.	Inviting tenders				
	6.1 WH	O product testing	38		
	6.2 Asse	ssment by national regulatory authorities	38		
	6.3 Risk WHO	management of rapid diagnostic tests not evaluated in the O programme	39		
Step 7.	Evaluating bids and awarding contracts				
	7.1 Prod	uct criteria	40		
	7.2 Supp	lier criteria	42		
	7.3 Com	mercial evaluation of bids	42		
	7.4 Awa	rding contracts	44		
Step 8.	Quality a	ssurance in procurement	46		
	8.1 ISO	13485 certification	46		
	8.2 Preq	ualification	48		
Step 9.	Quality control by lot testing				
	9.1 Intro	oduction	50		
	9.2 Gene	eral procedure	51		
	9.3 Samp	oling for lot testing	53		
	9.4 Repo	orting and interpreting the findings	54		
Step 10.	Transport, port clearance and receipt				
	10.1 Transport and temperature control requirements				
	10.2 Port	and customs clearance	55		
	10.3 Rece	ipt of each shipment	56		
	10.4 Verif	ication on receipt of shipment	56		
	10.5 Batcl	n traceability and recalls	57		
Step 11.	Monitori	ng	58		
_	11.1 Supp	lier performance	58		
	11.2 Prod	uct variations	59		
Step 12.	Continuo	us improvement	61		
Reference	ces	_	62		
Annexes	3		67		
	Annex 1.	Antigen production during the <i>Plasmodium</i> life cycle	68		
	Annex 2.	Mechanism of action of rapid diagnostic tests for malaria	70		
		Example of a procurement timeline			
		Panel detection score and diagnostic sensitivity			
	Annex 5.	Elements of supply management and quantification	76		
		Control and test line sequence			
	Annex 7.	Examples of regulatory device labelling and information requirements	81		
	Annex 8.	WHO product dossier for prequalification of diagnostics			
	Annex 9.	ISO 13485: Medical devices quality management system			
	Annex 10.	Lot-testing request form			
		Lot-testing report form			
Index		~ .	94		

Tables			
	Table 1.	Vulnerability of various components of rapid diagnostic tests for malaria	4
	Table 2.	Vulnerability in procurement of rapid diagnostic tests for malaria	5
	Table 3.	Antigen targets of rapid diagnostic tests for malaria	9
	Table 4.	Choice of rapid diagnostic test according to prevalence of malaria species	9
	Table 5.	Product specifications for rapid diagnostic tests for malaria	
	Table 6.	Reason for discrepancy between panel detection score and sensitivity	74
	Table 7.	Stock record card	77
	Table 8.	Labelling	81
	Table 9.	Product information	82
Figures			
	Figure 1.	Determination of panel detection score at low parasite density (200 parasites per microlitre)	11
	Figure 2.	Selection of an appropriate RDT for the intended area of use	16
	Figure 3.	Relations between suspected malaria cases that were tested and not tested (probable or unconfirmed) for malaria	19
	Figure 4.	Examples of different formats of RDT	25
	Figure 5.	Schematic representation of an RDT cassette	
	Figure 6.	Blood collection transfer devices	28
	Figure 7.	FIND interactive guide for malaria RDT product testing	30
	Figure 8.	FIND interactive guide: entry of selection criteria	
	Figure 9.	FIND interactive guide: results in chart view	31
	Figure 10.	Lot testing	53
	Figure 11.	RDT target antigens produced during the <i>Plasmodium</i> life cycle	68
	Figure 12.	Components and mechanism of RDT for malaria	71

Acknowledgements

The need for a manual such as this was identified at a meeting of the Roll Back Malaria Procurement and Supply Management Working Group, held on 9-10 July 2007 in Arlington, Virginia (USA), where it was agreed that WHO should be the technical agency responsible for preparing the manual. An outline was drafted by WHO Global Malaria Programme (WHO/GMP) secretariat (D.R. Bell, A. Bosman and S. Schwarte) on the basis of the WHO document, Good procurement practices for artemisinin-based antimalarial medicines (http://whqlibdoc.who.int/ publications/2010/9789241598927_eng.pdf). In mid-2010, WHO/GMP contracted Mr P. Hayes (Kingsway Management Services Ltd, United Kingdom) to prepare a draft document, which was sent for review to independent experts, who met at a WHO technical consultation held in Geneva on 22–23 September 2010.

The suggestions and contributions of the following reviewers are gratefully acknowledged: M. Aidoo (Centers for Disease Control and Prevention, USA), C. Asiimwe (Foundation for Innovative New Diagnostics, Uganda), L. Barat (United States Agency for International Development, USA), D.R. Bell (WHO/GMP), A. Bosman (WHO/GMP), C. Perez Casas (Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland), J. Paul Clark (World Bank, USA), V. D'Acremont (Swiss Tropical and Public Health Institute, Switzerland), D. Diop (Senegal National Pharmacy, Senegal), M. Dory (Médecins Sans Fontières, Belgium), A. Goliusov (World Bank, USA), H. den Besten (I+solutions, The Netherlands), N. Kyaterekera (National Medical Stores, Uganda), E. Lee (Foundation for Innovative New Diagnostics), S. Logez (Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland), W. Mbuthia (Kenya Medical Supplies Agency, Kenya), L. Nderimo (Medical Stores Department, United Republic of Tanzania), K. Neroutsos (Program for Appropriate Technology in Health, USA), D. Orozco (Médecins Sans Fontières, The Netherlands), R.B. Peck (Program for Appropriate Technology in Health, USA), L. Scheerlinck (United Nations Childrens' Fund Supply Division, Denmark), S. Schwarte (WHO/GMP), M. Sesay (United Nations Office for Project Services, India), R. Shretta (Management Sciences for Health/ Strengthening Pharmaceutical Systems), P. Stannard (United States Agency for International Development Deliver, John Snow Inc., USA) and D. Whybrew (Crown Agents, United Kingdom). On the basis of the input, P. Hayes, Rapporteur of the WHO consultation, prepared a second draft of the manual, which was sent to the same reviewers and also to representatives of the Association of Diagnostics Manufacturers of India, the European Diagnostic Manufacturers Association and representatives of 12 companies that manufacture rapid diagnostic test for malaria in compliance with WHO performance criteria. Precious suggestions that were instrumental to finalizing the document were received from: M. Aidoo, D.R. Bell, A. Bosman, M. Dory, Y.W. Kim, S. Korde, E. Lee, R. Newman, D. Orozco, Carmen Perez Casas and S. Schwarte. WHO greatly appreciates all the comments and suggestions received.

User feedback is welcomed, and improvements will be considered. Feedback can be sent by e-mail to infogmp@who.int, indicating in the subject line: 'Comments on WHO good practices for selecting and procuring of RDTs'.

Abbreviations

FIND Foundation for Innovative New Diagnostics

HRP2 histidine-rich protein 2

ISO International Organization for Standardization

pan all *Plasmodium* species

Pf *Plasmodium falciparum*

pLDH Plasmodium lactate dehydrogenase

Pv Plasmodium vivax

Pvom Plasmodium vivax, ovale and malariae

RDT rapid diagnostic test

TDR Special Programme for Research and Training in Tropical Diseases

WHO World Health Organization

预览已结束, 完整报告链接和

https://www.yunbaogao.cn/report/index/report?